Alveron Pharma
Alveron Pharma is developing OKL-1111, a synthetic anticoagulant and platelet inhibitor reversal agent, to improve outcomes for intracranial hemorrhage (ICH) patients. Current ICH treatments have lengthy administration times, while OKL-1111 offers a faster, more effective solution by binding to a downstream clotting factor and reversing the effects of clopidogrel. This accelerates treatment and improves patient outcomes.
Buy Funded Startups lists
Funding Round: Seed+
Funding Amount: €5M
Date: 06-Dec-2024
Investors: Broadview Ventures, Sanquin, Thuja Capital, Waterman Ventures, Oost NL
Markets: Biopharmaceuticals, Healthtech, Drug Discovery, Drug Delivery, Pharmaceuticals, Life Sciences
HQ: Oss, North Brabant, Netherlands
Founded: 2019
Website: https://www.alveron.com/
Leave a Comment
Comments
No comments yet.